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Introduction. RIFLE and AKIN provide a standardised classification of acute kidney injury (AKI), but their categorical rather than
continuous nature restricts their use to a research tool. A more accurate real-time description of renal function in AKI is needed,
and some published data suggest that equations based on serum creatinine that estimate glomerular filtration rate (eGFR) can
provide this. In addition, incorporating serum cystatin C concentration into estimates of GFR may improve their accuracy, but
no eGFR equations are validated in critically ill patients with AKI. Aim. This study tests whether creatinine or cystatin-C-based
eGFR equations, used in patients with CKD, offer an accurate representation of 4-hour creatinine clearance (4CrCl) in critically ill
patients with AKI. Methods. Fifty-one critically ill patients with AKI were recruited. Thirty-seven met inclusion criteria, and the
performance of eGFR equations was compared to 4CrCl. Results. eGFR equations were better than creatinine alone at predicting
4CrCl. Adding cystatin C to estimates did not improve the bias or add accuracy. The MDRD 7 eGFR had the best combination
of correlation, bias, percentage error and accuracy. None were near acceptable standards quoted in patients with chronic kidney
disease (CKD). Conclusions. eGFR equations are not sufficiently accurate for use in critically ill patients with AKI. Incorporating
serum cystatin C does not improve estimates. eGFR should not be used to describe renal function in patients with AKI. Standards
of accuracy for validating eGFR need to be set.
1. Introduction
There are numerous and inconsistent definitions of acute
kidney injury (AKI). The RIFLE criteria [1], which were
then modified to the AKIN criteria [2], form the basis
for classification of AKI; however, these classifications do
not provide an indication for when and how to alter the
management.Their categorical rather than continuous nature
is an important limitation in their use as a research tool. A
more accurate real time description of true renal function in
patients with AKI is needed.
In contrast, there are well-established techniques for
measuring and categorizing renal function in chronic kidney
disease (CKD). Glomerular filtration rate (GFR) is accepted
as the best overall measure of kidney function [3, 4]. The
gold standard for measurement of GFR is the urinary or
plasma clearance of an ideal filtration marker, such as inulin,
51Cr-EDTA (51Cr-ethylenediaminetetra-acetic acid), DTPA
(diethylene triamine penta-acetic acid), or iohexol. Mea-
suring clearance with these markers is complex, expensive,
and difficult to do in routine clinical practice [5]. As a
result, clearance of the endogenous biomarker creatinine
is the most widely used approach. Creatinine is found in
stable plasma concentrations, freely filtered, not reabsorbed,
and is minimally secreted by the renal tubule. Although
not the perfect marker, it is easily measured in blood and
urine and creatinine clearance (CrCl), over a defined time
interval (usually 24 hours), is used as a surrogate measure
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of GFR. Measuring 24-hour CrCl in patients with AKI and a
rapidly changing GFR will be misleading, but CrCl has been
validated in various groups of patients over much shorter
collection times (1, 2, 3, 4, and 8 hours) [6–10] including
patients in intensive care [11], and accurate urine collection
in critically ill patients is made easier by the use of urinary
catheters.
Clinicians now use a set of equations [12], which have
improved on the widely used Cockcroft and Galt (C&G)
formula to estimate renal function in patients with CKD [13]
and a GFR of 60mL⋅min−1 per 1.73m2 or less. Recently, an
eGFR equation modelled to accurately predict GFR over a
wider range, including values greater than 60mL⋅min−1 per
1.73m2, has been published [5], but this is not yet used in
routine clinical practice.
Some published data, albeit in abstract form, suggest that
MDRD eGFR calculations may be more useful than serum
creatinine alone in estimating renal function in critically
ill patients when compared to CrCl measurements [14, 15].
However, these eGFR equations have not been formally
validated for use in critically ill patients with AKI.
An attempt to improve the accuracy of eGFR has led
to new equations for patients with CKD that incorporate
the cysteine proteinase inhibitor cystatin C [16–21] (though
this has had varying success). Cystatin C is constitutively
expressed by all nucleated cells exhibiting a stable production
rate even in the presence of an acute inflammatory response
[16]. It is freely filtered by the glomerulus and almost
completely reabsorbed and catabolised by proximal tubular
epithelial cells [22]. eGFR equations with cystatin C as a
variable have not been tested as a marker of renal function
in critically ill patients with AKI.
As mentioned, CrCl measured over short-time periods
(e.g., four hours) is an accepted measure of renal function
in critically ill patients. It still; however, takes a significant
time to process and urine creatinine measurements are often
analysed once a day; thus the clinical picture may have
changed by the time the result is available. There is a need
for a quick and simple measurement that will provide a more
precise description of renal function than AKIN/RIFLE to
guide clinical practice and standardise research end points.
Simple equations that have been formulated to describe renal
function in CKDmay have a role in describing renal function
in AKI and be more sensitive than creatinine alone.
This study aimed to test whether creatinine or cystatin-
C-based eGFR equations, commonly used in patients with
CKD, offer an accurate representation of 4-hour CrCl (4CrCl)
(when less than 60mL⋅min−1 per 1.73m2) in critically ill
patients with AKI.
2. Methods
2.1. Patients and Sample Collection. This was a prospective
cohort analysis of critically ill patients with AKI. Approval
was obtained from a Research Ethics Committee that spe-
cialises in approving research involving patients with limited
or no capacity.Written informed consent was obtainedwhere
possible. If the patient was not able to consent, written
agreement for the patient to participate was obtained from
a consultee in accordance with the guidelines from the
ResearchEthicsCommittee in relation to theMental Capacity
Act of 2006 (UK).
All patients admitted to the adult general ICU were
considered if they had urinary and arterial catheters and
fulfilled one of the AKIN criteria. Urine was collected over
four hours, and a mixed sample was analysed for creatinine
concentration. Serum measurements were made at the end
of the collection time. Patient weight was determined from
the patients themselves or their relatives or, if neither of these
were possible, the most recent weight documented in the
medical notes. If none of these were available then weight
was estimated. Weight estimation is common in the ICU
occurring in approximately 40% of admissions in our centre
[23].When required, estimationwas performed jointly by the
nursing and medical staff. Body surface area was calculated
using the Mosteller formula [24]. Creatinine clearance was
determined by multiplying the urinary creatinine concentra-
tion by the rate of urine production and dividing by the serum
creatinine concentration.This was then standardised to body
surface area (1.73m2) for comparison with eGFR estimation.
Patients were excluded if 4CrCl was greater than
60mL⋅min−1 per 1.73m2 or the urine output was less than
0.24mL⋅kg−1 per hr over the study period (i.e., <400mL per
day in a 70 kg patient’s oliguria) as the clinical need to know
the actual GFR is less as renal replacement therapy beckons.
2.2. Calculations Using Equations Which Estimate GFR. The
equations used for estimating GFR are shown in Table 1
and include a comparison to serum creatinine alone [7, 14,
15, 18]. Creatinine was measured by the Jaffe reaction [25].
All these tests were performed on a Siemens ADVIA 2220
autoanalyser. Equations based on cystatin C are specific to
the method used for measurement. In this study, cystatin
C was measured using the particle-enhanced nephelometric
immunoassay (PENIA)method and thus the eGFR equations
used are those from the Levey group [16]. These appear to
be more accurate than its alternative, the particle-enhanced
turbidimetric immunoassay (PETIA) [26].
2.3. Statistical Analysis. Statistical analysis was done using
Microsoft Excel and GraphPad Prism 5 (v5.03). Two-tailed 𝑃
values < 0.05 were considered significant. Correlation coef-
ficients (Spearman’s rank) were calculated for each equation
compared to 4CrCl. Bland-Altman analysis [27] was used
to compare each equation to 4CrCl and the regression line
plotted. Bias is the mean of the difference between the eGFR
calculation and the 4CrCl. Percentage error or precision
was calculated by dividing the 1.96 multiple of the standard
deviation by the mean eGFR. Accuracy was measured as
the proportion of GFR estimates within 10%, 30% and 50%
deviation of the 4CrCl.
3. Results
51 patients had AKI as defined by AKIN but only 37 (20 male)
of those had a 4CrCl of ≤60mL⋅min−1 per 1.73m2 and a urine
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Cockcroft and Gault (140 − age) × weight
72 × sCr
× (0.85 if female)
aMDRD
175 × sCr−1.154 × age−0.203 × (0.742 if female) × (1.21 if black)
MDRD 6
198 × sCr−0.858 × age−0.167 × sUr−0.293 × uUr0.249 × 0.822 (if female) × 1.178 (if black)
MDRD 7
170 × sCr−0.999 × age−0.176 × sUr−0.170 × sAlb0.318 × 0.762 (if female) × 1.18 (if black)
CKD-EPI
Female






× 1.153 (if black)






× 1.153 (if black)







× 1.156 (if black)






× 1.156 (if black)
Cystatin C 1
76.7 × Cystatin C−1.19
Cystatin C 3
127.7 × Cystatin C−1.17 × age−0.13 × 0.91 (if female) × 1.06 (if black)
Cystatin C 4
177.6 × sCr−0.65 × Cystatin C−0.57 × age−0.2 × 0.82 (if female) × 1.11 (if black)
Age (years); weight (kg); sCr: serum creatinine (mg⋅dL−1) (to convert from 𝜇mol⋅L−1 divide by 88.4); sUr: serum Urea (mg⋅dL−1); uUr: urine urea (g⋅dL−1);
sAlb: serum albumin (mg⋅dL−1); cystatin C (mg⋅L−1); SDMA (nM⋅L−1).
output ≥0.24mL⋅kg−1 per hr. There was a broad range of
4CrCl over each of the AKIN criteria (Figure 1). Demo-
graphics and reason for ICU admission of the 37 patients
analysed are shown in Table 2. The mean (range) 4CrCl was
27.1 (8–51) mL⋅min−1 per 1.73m2. Table 3 summarises the
performance of the eGFR equations in terms of correlation,
bias, percentage error (precision), and accuracy. Figure 2
shows the accuracy of each of the equations. The MDRD 7
equation provided the most precise and accurate estimate of
creatinine clearance.
Cystatin C measurements were related to the AKIN cri-
teria and 4CrCl (Figure 3). There was a significant difference
between 1(R) and 3(F) (𝑃 < 0.001). Each category had a broad
range of distribution and substantial overlap between groups.
Cystatin C correlated significantly with 4CrCl (𝑟2 = 0.63; 𝑃 <
0.0001) (Figure 3).This wasmarginally better than creatinine
alone but not as good as the correlation coefficients for the
cystatin C equations.
All the eGFR equations were better than creatinine alone
at predicting the 4CrCl in terms of correlation, bias, precision,
and accuracy. The addition of cystatin C to the calculation
was better than creatinine alone but did not improve the
bias or add accuracy when compared to the original MDRD
equations and the new CKD-EPI equation. The MDRD 7
eGFR had the best overall combination of correlation, bias,
percentage error and accuracy.
4. Discussion
There is a need for a more accurate/continuous description



































Figure 1: The broad range of 4CrCl measured across the various
AKIN criteria in 51 critically ill patients with AKIN defined AKI.
for patients with AKI. For example, whereas volume over-
load, metabolic acidosis, hyperkalemia, and overt uraemic
manifestations are commonly accepted indications for renal
replacement therapy (RRT), initiation of therapy based on
other conditions is more subjective and based on clinical
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Table 2: Patient demographics (range).
Patients with AKI, a 4CrCl <
60mL⋅min−1 per 1.73m2 and a u/o >
0.24mL⋅kg−1 per hr
Number of patients 37








Height (cm) 170 (144–196)
Weight (kg) 82 (40–175)
Body surface area (m2) 1.95 (1.27–3.09)








AKI: acute kidney injury; 4CrCl: 4-hour creatinine clearance; u/o: urine
output.
judgement. Opinion differs on whether early RRTmay bene-
fit critically ill patients and the data up to 2007 [28] is difficult
to interpret due to the large variability in the parameters used
to trigger initiation of RRT [29–31]. This is supported by a
more recent study involving 54 ICUs which also struggles
to draw a firm conclusion about when to start RRT [32].
The ability to accurately describe renal function through the
consistency of a quantitive and continuous measure of renal
function may be more helpful than the descriptive scale of
the AKIN criteria when constructing similar, important trials
such as these.
AKI has secondary pathophysiological effects, for exam-
ple, increased risk of infection [33], contribution to the
development of multiorgan dysfunction syndrome [34], and
altered hepatic drug metabolism [35]. Volume overload
and acid-base derangements typical of renal dysfunction
have serious consequences in the duration and weaning of
mechanical ventilation [36]. Recent animal studies suggest
that acutely ischaemic kidneys may induce both functional
and transcriptional changes in the lung, independent of
uraemia [37]. Metabolic disturbances and some of the other
associated complications of AKI may be proportional to the
severity of renal injury again reinforcing the need to explore a
quantitative and continuous measure of renal function/GFR























































Figure 2: The accuracy of each of the equations expressed as the
percentage of estimates within 10%, 30% (P
30
), and 50%of the 4CrCl.
5. Measuring the ‘‘Clinical Success’’
of eGFR Equations
This study was designed to test the potential of using readily
available estimates of GFR as a bedside marker of renal func-
tion in critically ill patients with AKI to provide this measure.
In analysis there is a wide variation across different measures
of suitability (correlation, bias, precision, and accuracy) for
these eGFR equationswhich in turn raises the questions; what
is the best measure of suitability and what are the acceptable
limits?
The correlation coefficient in all equations (including
1/creatinine) could be deemed statistically strongm but in
this circumstance, it is not a good measure and is open to
misinterpretation. The Bland-Altman analysis reveals wide
ranges of both bias and percentage error for all equations,
highlighting that a small bias does not mean a more precise
equation. Acceptable limits of precision as less than or equal
to 30% have been suggested in comparisons of cardiac output
measures [38]. Based on these criteria, none of the eGFR
equations are satisfactory. Accuracy describes at best, only
27% of all the measures of MDRD 6 within 10% of the
measure 4CrCl with a maximum of 86% of eGFR measures
by theMDRD 7 equation being within 50% of the true 4CrCl.
There are no defined limits of acceptability when compar-
ing measured and estimated GFR but previous publications
offer some guidance. Levey et al. [12] noted that small reduc-
tions in correlation coefficient can represent large increases
in unexplained variance but continue to use this as a marker
of accuracy. The paper also demonstrates that the equations
perform better and are more accurate than in this study.
Subsequent studies consistently publish a P
30
(the percentage
of values estimated that are accurate to within 30% of the true
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Table 3: A summary of the performance of eGFR equations in critically ill patients with AKI, whose 4CrCl was less than 60mL⋅min−1 per
1.73m2 and whose urine output was greater than 0.2mL⋅kg−1 per min during the study period (37 patients).








(mL⋅min−1 per 1.73m2) 27.1
∗ 53.4 35.5 33.3 35.5 28.8 32.3 43.2 41.0 39.7
Range
(mL⋅min−1 per 1.73m2) 8–51 13–119 11–63 9–87 9–79 8–71 9–80 17–85 16–79 15–79
r 2 correlation (P < 0.0001) 0.64 0.82 0.72 0.75 0.71 0.70 0.71 0.71 0.70
Bias −26.3 −8.4 −6.2 −5.4 −1.6 −5.2 −16.1 −13.9 −12.5
(1.96 × SD) 28 13.72 18.6 16.66 16.6 18.33 20.14 19.36 16.6
Percentage error (precision) 52 39 56 47 58 57 46 47 42
Accuracy (%)




5 46 57 49 70 57 27 30 35
50% 22 68 78 76 86 81 46 54 59
∗Measured not estimated.
value) which is perhapsmore useful comparison hence its use
in this analysis.
A recent study of eGFR performance in renal transplant
patients, [39] used Bland-Altman analysis and described the
bias of C&G, aMDRD, and MDRD 7 as 15.2, 9.2, and 7.4
and worse than this study. The precision (25.4%, 21.9%, and
20%, resp.) however, was better and within a range suggested
previously [38]. The percentage of values within 30% of the
4CrCl (P
30
) (37, 60, and 67.4, resp.) was comparable to the
data from this study, and the use of the equations in renal
transplant recipients is recommended.
When introduced, theCKD-EPI equation [7] had a bias of
2.1mL⋅min−1 per 1.73m2 and a P
30
of 79.9%, which are better
than data presented in this study and comparable only to the
MDRD 7 equation.
Using methods based on cystatin C when compared
with methods incorporating serum creatinine have shown
a higher correlation and improved accuracy in predicting
GFR in patients with various degrees of renal function, liver
disease, and spinal cord injuries [17]. However, results in
patients with diabetes, paediatric patients, and those with
early renal impairment did not show a significant difference
between cystatin C and creatinine based eGFR, indicating
that the performancemay be patient population specific [40–
43]. Human studies also suggest that cystatin C can predict
the development of AKI [44] and the requirement for renal
replacement therapy [45], although its superiority over serum
creatinine has not been a universal finding [46].
Data presented in this study demonstrate a very broad
range of both 4CrCl and cystatin C measurement across
each of the AKIN/RIFLE criteria. Figure 3 shows that serum
cystatin C increased with worsening renal functionmeasured
by 4CrCl, but the correlation coefficient is not compelling and
the confidence intervals are wide. When originally derived,
the equations which incorporate cystatin C showed minimal
bias and excellent accuracy with P
30
of 81%, 83%, and 89%
for cystatin C1, C3, and C4 equations, respectively [16].These
results were not reproduced in this study and the cystatin C
equations actually perform worse than the original MDRD
equations in patients with AKI.
6. Limitations
Measuring rapid changes in renal function accurately in
critically ill patients is difficult and there is no gold standard
method. A useful, routine exogenous marker has remained
elusive and there are well-described difficulties when inter-
preting creatinine clearance. Tubular secretion and extrarenal
elimination of creatinine increases as GFR deteriorates,
thus exaggerating the discrepancy between the clearance of
creatinine and true renal function [47]. In addition, serum
creatinine concentrations are influenced by muscle mass,
protein intake, gender, and age, limiting the precision further.
The influence of these factors in the acute setting is not
clear. However, over a period of hours and days, as the renal
function deteriorates in AKI, one would anticipate that these
other factors would remain relatively constant.
Aware of its limitations, in the absence of an accepted
gold standard, the 4CrCl was piloted as a baseline standard.
It incorporates both changes in creatinine and urine output
and is supported by an evidence base. A small study of
eighteen critically ill patients used correlation coefficients to
compare clearance of DTPA or inulin (their gold-standard
measure) to 2-hour creatinine clearance (2CrCl) [48]. The
authors conclude that a 2CrCl is not an accurate description
of inulin clearance, in this population, when the GFR is
<30mL⋅min−1. However, reanalysis of the published raw data
reveals a correlation coefficient (𝑟) between DTPA and 2-
hour creatinine clearance of 0.92 (𝑃 < 0.001) though this
is not discussed in the original paper. Perhaps the more
encouraging conclusion should include the close relationship
with DTPA clearance. There is no mention of urine volume
during the study time period and patients with very low
DTPA clearances (2mL⋅min−1) were included.
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Figure 3: Wide range of serum cystatin C across the corresponding
AKIN criteria and the correlation between 4CrCl and cystatin C
(𝑟2 = 0.63; 𝑃 < 0.0001).
On balance, until a comprehensive study is designed
using a universally accepted gold-standard measure of GFR,
we feel that 4CrCl is the most practical measure of GFR at
any one time in this specific and rapidly changing clinical
scenario.
This is a small single centre study but the first direct
comparison of a direct measure of renal function and mathe-
matical estimations in critically ill patients. Our conclusions
are important to discourage the misinterpretation of eGFR
equations in patients with AKI but also to encourage a search
for a more robust method of measuring renal function
other than 4CrCl and promote the consideration of a larger
multicentre study.
7. Conclusion
Although our study population is small, we conclude that the
MDRD equations, which estimate GFR, do not accurately
predict renal function measured by 4CrCl and thus are not
accurate enough for clinical use in critically ill patients with
AKI. Although the results in this study are in fact better
than any others published in critically ill patients so far, we
consider that previous results have been over interpreted in
favour of using GFR calculations and if a larger study was
designed, a dramatic improvement in performance would be
needed to show clinical relevance of these estimations. Serum
cystatin C measurements, and equations which incorporate,
do not add further information when estimating 4CrCl and
should not be used in their current format in clinical practice
to describe GFR.
In the future, modifications incorporating the unique
circumstances of critical illness may add value to the eGFR
calculations. For example, in critical illness, redistribution
of albumin to the interstitial compartment causes the serum
albumin concentration to be low, thus its inclusion as part of
eGFR may not be helpful. Weight is also difficult to measure
accurately in the ICU and patients often have many litres
of excess extravascular fluid and thus even measured weight
may not reflect true weight when euvolaemic. Consideration
of “AKI limits” such as oliguria or anuria may also help along
with, if possible, a comparison to a gold-standard measure of
renal function in AKI which could confirm the validity of a
4CrCl.
Finally, a consensus needs to be reached when setting
performance targets of new eGFR equations. Bias, percentage
error, and P
30
are commonly reported, but a range of
acceptability has not yet been set.
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